Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2008
Coronary artery calcification in patients with primary hyperparathyroidism in comparison with control subjects from the multi-ethnic study of atherosclerosis.
Сравнительное исследованиеСтатьяПоддержка NIH: внешняя программаНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Streeten Elizabeth A, Munir Kashif, Hines Scott, Mohamed Asif, Mangano Charles, Ryan Kathleen A, Post Wendy
Аннотация
OBJECTIVE: To determine whether coronary artery calcification (CAC) is increased in patients with primary hyperparathyroidism (pHPT) because of the presence of hypercalcemia, which has been shown in vitro to promote vascular calcification.
METHODS: Electron beam computed tomography of the coronary arteries was performed on 20 patients with pHPT referred to our endocrinology clinic for evaluation of hypercalcemia. All patients were nonsmokers, with normal renal function, no history of diabetes, and no history of coronary artery disease. CAC in the patients with pHPT was compared with that in population-based control subjects from the Multi-Ethnic Study of Atherosclerosis (MESA). Two methods of analysis were used: (1) calculation of the odds ratio of CAC and (2) a nested case-control (1:4) study.
RESULTS: One patient with pHPT had a history of nephrolithiasis; the other 19 patients were asymptomatic. The mean age (+/- SD) of the patients with pHPT was 57.3 +/- 9.1 years, the mean serum calcium concentration was 2.68 +/- 0.18 mmol/L, and the mean intact parathyroid hormone level was 119 +/- 76.5 pg/mL. Of the 20 patients, 14 had CAC scores of zero. The odds ratio for measurable CAC in the presence of pHPT in comparison with that in the MESA control subjects was 0.17, which was not significant. In the matched analysis, the CAC scores for the patients with pHPT did not differ significantly from those for the MESA control subjects (P = 0.25 with use of the Wilcoxon test).
CONCLUSION: We found no evidence for a difference in CAC in patients with pHPT in comparison with the population-based control subjects in this small pilot study.
METHODS: Electron beam computed tomography of the coronary arteries was performed on 20 patients with pHPT referred to our endocrinology clinic for evaluation of hypercalcemia. All patients were nonsmokers, with normal renal function, no history of diabetes, and no history of coronary artery disease. CAC in the patients with pHPT was compared with that in population-based control subjects from the Multi-Ethnic Study of Atherosclerosis (MESA). Two methods of analysis were used: (1) calculation of the odds ratio of CAC and (2) a nested case-control (1:4) study.
RESULTS: One patient with pHPT had a history of nephrolithiasis; the other 19 patients were asymptomatic. The mean age (+/- SD) of the patients with pHPT was 57.3 +/- 9.1 years, the mean serum calcium concentration was 2.68 +/- 0.18 mmol/L, and the mean intact parathyroid hormone level was 119 +/- 76.5 pg/mL. Of the 20 patients, 14 had CAC scores of zero. The odds ratio for measurable CAC in the presence of pHPT in comparison with that in the MESA control subjects was 0.17, which was not significant. In the matched analysis, the CAC scores for the patients with pHPT did not differ significantly from those for the MESA control subjects (P = 0.25 with use of the Wilcoxon test).
CONCLUSION: We found no evidence for a difference in CAC in patients with pHPT in comparison with the population-based control subjects in this small pilot study.